Proposed LDT Rule Is The Biggest Impact Event of 2023 in FDA Regulatory Space
There were many developments at the FDA last year such as the approval of multiple cell and gene therapy products, the first CRISPR product approval, the formal end of the pandemic, the rise of remote inspections, and the retirement of the legendary Janet Woodcock. However, the one action by the FDA that would likely have … Read more